logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Targeted Radionuclide Tumor Therapy Biological Aspects 1st Edition Torgny Stigbrand

  • SKU: BELL-1996264
Targeted Radionuclide Tumor Therapy Biological Aspects 1st Edition Torgny Stigbrand
$ 35.00 $ 45.00 (-22%)

4.0

36 reviews

Targeted Radionuclide Tumor Therapy Biological Aspects 1st Edition Torgny Stigbrand instant download after payment.

Publisher: Springer
File Extension: PDF
File size: 5.7 MB
Pages: 416
Author: Torgny Stigbrand, Jorgen Carlsson, Gregory P. Adams
ISBN: 9781402086953, 1402086954
Language: English
Year: 2008
Edition: 1

Product desciption

Targeted Radionuclide Tumor Therapy Biological Aspects 1st Edition Torgny Stigbrand by Torgny Stigbrand, Jorgen Carlsson, Gregory P. Adams 9781402086953, 1402086954 instant download after payment.

The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. The expanding array of new targeting molecules (recombinant antibodies or peptides) may increase the therapeutic efficacy. The title of this book "Targeted Radionuclide Tumor Therapy – Biological aspects" was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation. Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future. The development of targeted therapy is a true multidisciplinary enterprise involving physician scientists from the fields of nuclear medicine, radiation therapy, diagnostic radiology, surgery, gynaecology, pathology and medical oncology/haematology. It also involves many preclinical scientists working with experimental animal models, immunochemistry, recombinant antibody technologies, radiochemistry, radiation physics and basic cell biology. It is the ambition of the editors to enable deeper insights in the process of improving targeted therapy. We believe that the time now has come when targeted therapy can soon be added to standard oncology treatment regimens.

Related Products